Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-ΚB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells

Rheumatology

Volumn 49, Issue 8, 2010, Pages 1447-1460

  Choo, Qiu Yi ^a   Ho, Paul C ^a   Tanaka, Yoshiya ^b   Lin, Hai Shu ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Angiogenesis; Histone deacetylase inhibitor; Metalloproteinase; MS 275; NF B; Nitric oxide; P21; Pro inflammatory cytokines; Rheumatoid arthritis; Suberoylanilide hydroxamic acid

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CYTOKINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NITRIC OXIDE; P21 ACTIVATED KINASE 1; PROTEIN P300; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VORINOSTAT;

ANIMAL CELL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ARTHRITIS, RHEUMATOID; BENZAMIDES; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; FIBROBLASTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LIPOPOLYSACCHARIDES; MACROPHAGES; METALLOPROTEASES; MICE; MODELS, BIOLOGICAL; NF-KAPPA B; NITRIC ACID; PYRIDINES; SYNOVIAL MEMBRANE;

EID: 77954752923     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq108     Document Type: Article

References (55)

1. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
2. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
3. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
4. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007;6:21-2.
5. Choo QY, Ho PC, Lin HS. Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharm Des 2008; 14:803-20.
6. ClinicalTrials.gov. A service of the US National Institutes of Health. http://www.clinicaltrials.gov (15 January 2010, date last accessed).
7. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007;150:829-31.
8. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009;9:309-19.
9. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003;8:707-17.
10. Nasu Y, Nishida K, Miyazawa S et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr Cartil 2008;16:723-32.
11. Mori H, Abe F, Furukawa S et al. Fr235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC) ii. Biological activities in animal models. J Antibiot 2003;56:80-6.
12. Manabe H, Nasu Y, Komiyama T et al. Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm Res 2008;57:4-10.
13. Nakamura T, Kukita T, Shobuike T et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-16.
14. Nishida K, Komiyama T, Miyazawa S et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16ink4a and p21(waf1/cip1) expression. Arthritis Rheum 2004;50:3365-76.
15. Lin HS, Hu CY, Chan HY et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150:862-72.
16. Abe M, Tanaka Y, Saito K et al. Regulation of interleukin (IL)-1beta gene transcription induced by IL-1beta in rheumatoid synovial fibroblast-like cells, E11, transformed with simian virus 40 large t antigen. J Rheumatol 1997;24: 420-9.
17. Nakatsuka K, Tanaka Y, Hubscher S et al. Rheumatoid synovial fibroblasts are stimulated by the cellular adhesion to T cells through lymphocyte function associated antigen-1/intercellular adhesion molecule-1. J Rheumatol 1997;24:458-64.
18. American Type Culture Collection. MTT cell proliferation assay instructions. http://www.Atcc.Org/portals/1/pdf/30-1010k.Pdf (15 January 2010, date last accessed).
19. Du YH, Ho PC. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and-resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 2001;47:481-90.
20. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988;141:2407-12.
21. NIH. Imagej. http://rsbweb.Nih.Gov/ij/index.Html (15 January 2010, date last accessed).
22. Yoshifuji H, Umehara H, Maruyama H et al. Amelioration of experimental arthritis by a calpain-inhibitory compound: regulation of cytokine production by e-64-d in vivo and in vitro. Int Immunol 2005;17:1327-36.
23. Pierce JW, Schoenleber R, Jesmok G et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272: 21096-103.
24. Garcia MG, Alaniz L, Lopes EC, Blanco G, Hajos SE, Alvarez E. Inhibition of NF-kappaB activity by Bay 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005;29:1425-34.
25. Nakahara H, Song J, Sugimoto M et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9.
26. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999;39: 295-312.
27. Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001;3:200-6.
28. Firestein GS. NF-kappa B: holy grail for rheumatoid arthritis? Arthritis Rheum 2004;50:2381-6.
29. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil 2006;14:839-48.
30. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
31. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-11.
32. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metallo-proteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59: 455-61.
33. Tchetverikov I, Ronday HK, van El B et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63:881-3.
34. Huber LC, Brock M, Hemmatazad H et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007;56:1087-93.
35. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009;36:1580-9.
36. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006;45:669-75.
37. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
38. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005; 115:118-28.
39. Sharpless NE, Bardeesy N, Lee KH et al. Loss of p16(INK4a) with retention of p19(ARF) predisposes mice to tumorigenesis. Nature 2001;413:86-91.
40. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001;61:6234-8.
41. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
42. Taniguchi K, Kohsaka H, Inoue N et al. Induction of the p16(INK4a) senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999;5:760-7.
43. Perlman H, Bradley K, Liu HT et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunology 2003;170:838-45.
44. Nasu K, Kohsaka H, Nonomura Y et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000;165: 7246-52.
45. Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints. Int Immunol 2001;13: 723-31.
46. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003;171: 4913-9.
47. Morinobu A, Wang B, Liu J, Yoshiya S, Kurosaka M, Kumagai S. Trichostatin A cooperates with Fasmediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2006;33: 1052-60.
48. Nakamura C, Matsushita I, Kosaka E, Kondo T, Kimura T. Anti-arthritic effects of combined treatment with histone deacetylase inhibitor and low-intensity ultrasound in the presence of microbubbles in human rheumatoid synovial cells. Rheumatology 2008;47:418-24.
49. Jungel A, Baresova V, Ospelt C et al. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for trail-induced apoptosis. Ann Rheum Dis 2006;65:910-2.
50. Li X, Makarov SS. An essential role of NF-kappaB in the 'Tumor-like' phenotype of arthritic synoviocytes. Proc Natl Acad Sci USA 2006;103:17432-7.
51. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2: 473-88.
52. Kiernan R, Bres V, Ng RW et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278:2758-66.
53. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009;41:185-98.
54. Greene WC, Chen LF. Regulation of NF-kappaB action by reversible acetylation. Novartis Found Symp 2004;259: 208-17, Discussion 18-25.
55. Chen LF, Greene WC. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 2003;81:549-57.